在接受利福平治疗的患有骨科设备相关感染的患者的皮肤和鼻子上出现耐利福平葡萄球菌。
Emergence of rifampicin-resistant staphylococci on the skin and nose of rifampicin-treated patients with an orthopaedic-device-related infection.
作者信息
Wallimann Alexandra, Achermann Yvonne, Ferris Ciara, Morgenstern Mario, Clauss Martin, Stadelmann Vincent, Rüdiger Hannes Andreas, O'Mahony Liam, Moriarty Thomas Fintan
机构信息
AO Research Institute Davos, Davos, Switzerland.
Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland.
出版信息
J Bone Jt Infect. 2024 Jul 24;9(4):191-196. doi: 10.5194/jbji-9-191-2024. eCollection 2024.
Abstract
Rifampicin is a key antibiotic in the treatment of staphylococcal biofilm infections. In this pilot study, we found that patients who received rifampicin for treatment of an orthopaedic-device-related infection (ODRI) were colonized with rifampicin-resistant staphylococci during treatment and this persisted for up to 2 months after cessation of treatment.
摘要
利福平是治疗葡萄球菌生物膜感染的关键抗生素。在这项初步研究中，我们发现接受利福平治疗骨科器械相关感染（ODRI）的患者在治疗期间被耐利福平葡萄球菌定植，并且在治疗停止后这种情况持续长达2个月。
相似文献
1
Emergence of rifampicin-resistant staphylococci on the skin and nose of rifampicin-treated patients with an orthopaedic-device-related infection.在接受利福平治疗的患有骨科设备相关感染的患者的皮肤和鼻子上出现耐利福平葡萄球菌。
J Bone Jt Infect. 2024 Jul 24;9(4):191-196. doi: 10.5194/jbji-9-191-2024. eCollection 2024.
2
Staphylococcal orthopaedic device-related infections in older patients.老年患者中与骨科器械相关的葡萄球菌感染
Injury. 2016 Jul;47(7):1427-34. doi: 10.1016/j.injury.2016.04.027. Epub 2016 May 2.
3
Tolerant Small-colony Variants Form Prior to Resistance Within a Staphylococcus aureus Biofilm Based on Antibiotic Selective Pressure.耐小菌落变异体在基于抗生素选择压力的金黄色葡萄球菌生物膜内形成耐药之前形成。
Clin Orthop Relat Res. 2021 Jul 1;479(7):1471-1481. doi: 10.1097/CORR.0000000000001740.
4
Early Staphylococcal Periprosthetic Joint Infection (PJI) Treated with Debridement, Antibiotics, and Implant Retention (DAIR): Inferior Outcomes in Patients with Staphylococci Resistant to Rifampicin.采用清创、抗生素和保留植入物（DAIR）治疗的早期葡萄球菌假体周围关节感染（PJI）：对利福平耐药葡萄球菌患者的预后较差。
Antibiotics (Basel). 2023 Nov 3;12(11):1589. doi: 10.3390/antibiotics12111589.
5
Oral treatment of Staphylococcus spp. infected orthopaedic implants with fusidic acid or ofloxacin in combination with rifampicin.用夫西地酸或氧氟沙星联合利福平对感染葡萄球菌属的骨科植入物进行口服治疗。
J Antimicrob Chemother. 1997 Feb;39(2):235-40. doi: 10.1093/jac/39.2.235.
6
Genomics of Staphylococcus aureus and Staphylococcus epidermidis from Periprosthetic Joint Infections and Correlation to Clinical Outcome.假体周围关节感染的金黄色葡萄球菌和表皮葡萄球菌的基因组学及其与临床结果的相关性。
Microbiol Spectr. 2022 Aug 31;10(4):e0218121. doi: 10.1128/spectrum.02181-21. Epub 2022 Jun 28.
7
Clinical presentation and treatment of orthopaedic implant-associated infection.骨科植入物相关感染的临床表现与治疗。
J Intern Med. 2014 Aug;276(2):111-9. doi: 10.1111/joim.12233.
8
An Enzybiotic Regimen for the Treatment of Methicillin-Resistant Orthopaedic Device-Related Infection.一种用于治疗耐甲氧西林骨科器械相关感染的酶生素方案。
Antibiotics (Basel). 2021 Sep 29;10(10):1186. doi: 10.3390/antibiotics10101186.
9
Decreased serum linezolid concentrations in two patients receiving linezolid and rifampicin due to bone infections.两名因骨感染同时接受利奈唑胺和利福平治疗的患者血清利奈唑胺浓度降低。
Scand J Infect Dis. 2012 Jul;44(7):548-50. doi: 10.3109/00365548.2012.663931. Epub 2012 Mar 4.
10
Antimicrobial peptides (AMP) in biofilm induced orthopaedic device-related infections.生物膜中抗菌肽（AMP）引发的骨科器械相关感染。
J Clin Orthop Trauma. 2022 Jan 26;25:101780. doi: 10.1016/j.jcot.2022.101780. eCollection 2022 Feb.
本文引用的文献
1
Skeletal infections: microbial pathogenesis, immunity and clinical management.骨骼感染：微生物发病机制、免疫与临床管理。
Nat Rev Microbiol. 2022 Jul;20(7):385-400. doi: 10.1038/s41579-022-00686-0. Epub 2022 Feb 15.
2
Role of Rifampin against Staphylococcal Biofilm Infections , in Animal Models, and in Orthopedic-Device-Related Infections.利福平对抗葡萄球菌生物膜感染的作用：在动物模型和骨科器械相关感染中的作用。
Antimicrob Agents Chemother. 2019 Jan 29;63(2). doi: 10.1128/AAC.01746-18. Print 2019 Feb.
3
Rifampicin resistance in Staphylococcus epidermidis: molecular characterisation and fitness cost of rpoB mutations.表皮葡萄球菌利福平耐药性：rpoB 突变的分子特征和适应代价。
Int J Antimicrob Agents. 2018 May;51(5):670-677. doi: 10.1016/j.ijantimicag.2017.12.019. Epub 2017 Dec 26.
4
Resistance to rifampicin: a review.对利福平的耐药性：综述
J Antibiot (Tokyo). 2014 Sep;67(9):625-30. doi: 10.1038/ja.2014.107. Epub 2014 Aug 13.
5
Factors associated with rifampin resistance in staphylococcal periprosthetic joint infections (PJI): a matched case-control study.与葡萄球菌假体周围关节感染（PJI）中利福平耐药相关的因素：一项匹配的病例对照研究。
Infection. 2013 Apr;41(2):431-7. doi: 10.1007/s15010-012-0325-7. Epub 2012 Sep 19.
6
Emergence of rifampicin resistance during rifampicin-containing treatment in elderly patients with persistent methicillin-resistant Staphylococcus aureus bacteremia.老年持续性耐甲氧西林金黄色葡萄球菌菌血症患者在含利福平治疗期间出现利福平耐药。
J Am Geriatr Soc. 2010 May;58(5):1001-3. doi: 10.1111/j.1532-5415.2010.02842.x.
7
Molecular characterization of resistance to Rifampicin in an emerging hospital-associated Methicillin-resistant Staphylococcus aureus clone ST228, Spain.西班牙出现的耐甲氧西林金黄色葡萄球菌克隆株 ST228 对利福平耐药性的分子特征
BMC Microbiol. 2010 Mar 4;10:68. doi: 10.1186/1471-2180-10-68.
8
Antibiotic susceptibility among Staphylococcus epidermidis isolated from prosthetic joint infections with special focus on rifampicin and variability of the rpoB gene.从人工关节感染中分离出的表皮葡萄球菌的抗生素敏感性，特别关注利福平及rpoB基因的变异性。
Clin Microbiol Infect. 2009 Mar;15(3):238-44. doi: 10.1111/j.1469-0691.2008.02663.x. Epub 2009 Jan 22.
9
Emergence and spread of rifampicin-resistant, methicillin-resistant Staphylococcus aureus during vancomycin-rifampicin combination therapy in an intensive care unit.
Eur J Clin Microbiol Infect Dis. 2006 Jan;25(1):61-2. doi: 10.1007/s10096-005-0063-1.
10
Molecular basis of rifampin resistance in Streptococcus pneumoniae.肺炎链球菌中利福平耐药性的分子基础。
Antimicrob Agents Chemother. 1999 Oct;43(10):2361-5. doi: 10.1128/AAC.43.10.2361.
Zotero 插件